23.86
전일 마감가:
$24.90
열려 있는:
$24.9
하루 거래량:
740.52K
Relative Volume:
0.67
시가총액:
$3.20B
수익:
-
순이익/손실:
$-151.09M
주가수익비율:
-15.29
EPS:
-1.56
순현금흐름:
$-160.51M
1주 성능:
-3.15%
1개월 성능:
+1.97%
6개월 성능:
+74.05%
1년 성능:
+51.17%
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
명칭
Centessa Pharmaceuticals Plc Adr
전화
44 7391 789784
주소
3RD FLOOR, ALTRINCHAM, CHESHIRE
CNTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
CNTA
Centessa Pharmaceuticals Plc Adr
|
23.86 | 3.34B | 0 | -151.09M | -160.51M | -1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.23 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.92 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.67 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.18 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.14 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-28 | 개시 | Stephens | Overweight |
| 2025-09-03 | 개시 | Wells Fargo | Overweight |
| 2025-08-29 | 재개 | Oppenheimer | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-05-08 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-31 | 개시 | Piper Sandler | Overweight |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-09-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-19 | 개시 | B. Riley Securities | Buy |
| 2024-07-18 | 개시 | Oppenheimer | Outperform |
| 2023-11-15 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-10-26 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-06-21 | 개시 | Evercore ISI | Outperform |
| 2023-06-12 | 개시 | Guggenheim | Buy |
| 2023-03-17 | 개시 | SVB Securities | Outperform |
| 2022-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-06-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-02-11 | 개시 | Goldman | Neutral |
모두보기
Centessa Pharmaceuticals Plc Adr 주식(CNTA)의 최신 뉴스
Centessa Pharmaceuticals stock hits 52-week high at 25.35 USD - Investing.com
Centessa Pharmaceuticals (CNTA) – Research Analysts’ Weekly Ratings Changes - Defense World
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025 - GlobeNewswire Inc.
Mario Alberto Accardi Sells 8,000 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock - MarketBeat
Centessa Pharma (CNTA) president sells $200k in shares - Investing.com India
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at $24.65 - Investing.com India
Centessa Pharmaceuticals stock hits 52-week high at $24.65 By Investing.com - Investing.com Philippines
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Bought by Windmill Hill Asset Management Ltd - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Stake Reduced by GAMMA Investing LLC - Defense World
Centessa Pharmaceuticals (CNTA) Receives a Buy from Piper Sandler - The Globe and Mail
Tanager Wealth Management LLP Decreases Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Platinum Investment Management Ltd. Has $3.82 Million Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Wells Fargo Sticks to Its Buy Rating for Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Centessa Pharmaceuticals (NASDAQ:CNTA) Hits New 12-Month HighWhat's Next? - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at 24.17 USD By Investing.com - Investing.com Nigeria
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of “Buy” by Brokerages - Defense World
Centessa Pharmaceuticals stock hits 52-week high at 24.17 USD - Investing.com India
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 1-Year HighTime to Buy? - MarketBeat
Centessa Pharmaceuticals’ Bush sells $840,000 in shares - Investing.com India
Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) CTO Sells $840,000.00 in Stock - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 12-Month HighHere's What Happened - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 1-Year High – Should You Buy? - Defense World
Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells 8,172 Shares of Stock - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at 23.51 USD By Investing.com - Investing.com Australia
Centessa Pharmaceuticals (NASDAQ:CNTA) General Counsel Iqbal J. Hussain Sells 6,000 Shares - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at 23.51 USD - Investing.com
Woodline Partners LP Lowers Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Ellsworth Advisors LLC Buys Shares of 48,872 Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Fred Alger Management LLC Has $2.11 Million Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa Pharma general counsel sells $131k in shares By Investing.com - Investing.com South Africa
Centessa Pharma general counsel sells $131k in shares - Investing.com India
Centessa Pharmaceuticals (NASDAQ:CNTA) Hits New 1-Year HighShould You Buy? - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap UpHere's Why - MarketBeat
Centessa Pharmaceuticals Plc Adr (CNTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):